Allogene Therapeutics Cash Flow Statement (2018-2026) | ALLO

Cash Flow Statement Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating Activities
Net Income (Quarter)
-70.41M-77.28M1.89M-79.52M-76.30M-81.51M-93.64M-97.03M-76.76M-56.79M-78.84M-64.07M-66.44M-65.17M-57.54M-59.83M-50.90M-41.32M-39.06M-42.82M
Depreciation and Depletion (Quarter)
1.96M2.33M4.24M3.69M3.67M3.86M3.07M3.51M3.64M3.57M3.48M3.56M
Share-based Compensation (Quarter)
21.13M20.86M22.04M22.32M22.89M21.15M17.25M18.77M16.59M15.35M15.23M11.92M13.56M13.39M12.87M12.18M8.69M8.65M8.13M8.27M
Deferred Taxes (Quarter)
Gains from Investment Securities (Quarter)
15.14M-14.95M19.09M3.11M-0.31M0.41M28.15M-0.04M0.10M3.00M7.00M-1.45M3.85M-6.69M-0.42M1.93M-1.50M-0.08M
Asset Writedowns and Impairment (Quarter)
9.50M5.00M10.73M-0.02M2.38M
Non-cash Items (Quarter)
Cash from Operations (Quarter)
-41.17M-48.88M-45.44M-68.24M-42.53M-47.66M-62.10M-66.64M-61.86M-55.53M-53.71M-55.90M-63.59M-44.12M-36.70M-52.93M-39.03M-29.69M-27.60M-12.91M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
-1.83M-1.61M-1.59M-1.33M-0.91M-0.49M-0.16M-0.51M1.07M2.94M3.30M2.80M2.20M1.70M1.65M1.31M1.17M0.92M0.82M0.89M
Depreciation & Amortization (CF) (Quarter)
1.96M2.33M4.24M3.69M3.67M3.86M3.07M3.51M3.64M3.57M3.48M3.56M3.64M3.21M3.19M3.10M3.11M3.10M3.10M2.87M
Change in Working Capital
Change in Account Payables (Quarter)
-3.06M0.19M-2.04M-0.51M1.42M1.01M2.94M1.06M-4.29M-3.97M-0.30M-0.12M6.81M-7.23M0.03M-0.34M-0.42M-1.07M0.60M0.66M
Change in Accured Expenses (Quarter)
1.84M8.89M-2.77M-9.05M5.71M1.95M3.14M5.69M-0.08M-12.72M0.29M-5.69M-0.98M2.53M2.88M-5.22M1.74M1.09M-0.12M-5.10M
Investing Activities
Capital Expenditures (Quarter)
9.06M3.35M-18.98M1.90M1.37M0.22M-2.82M1.03M0.29M0.01M0.18M0.01M0.43M0.26M0.21M0.17M-0.28M0.01M
Change in Acquisitions & Divestments (Quarter)
215.82M161.78M-645.85M68.68M-68.68M143.44M152.87M-290.69M103.27M117.22M109.80M-324.90M56.50M53.80M61.91M61.99M72.11M
Cash from Investing Activities (Quarter)
24.59M13.01M29.25M-22.38M54.03M24.91M49.60M112.94M17.16M-34.27M67.46M22.13M74.61M-75.99M54.93M6.18M43.84M11.94M33.61M-29.59M
Financing Activities
Other financing activities (Quarter)
2.28M3.35M3.56M
Debt Issuance and Repayment
Long-Term Debt Issuances (Quarter)
Change in Capital Stock
Shares Issued (Quarter)
5.29M-3.66M-3.62M0.28M1.25M-1.09M-0.44M1.61M0.33M0.56M0.86M-0.04M0.90M0.00M
Preferred Shares Issued (Quarter)
Misc.
Cash from Financing Activities (Quarter)
3.21M2.38M0.32M1.81M0.02M1.07M0.05M1.73M89.52M4.29M0.15M1.65M108.60M0.68M5.74M13.99M5.07M3.24M7.86M21.12M
Change in Cash (Quarter)
-13.36M-33.48M-15.86M-88.80M11.53M-21.68M-12.45M48.03M44.83M-85.51M13.91M-32.12M119.63M-119.43M23.98M-32.76M9.88M-14.52M13.87M-21.38M
Free Cash Flow (Quarter)
-50.23M-52.23M-26.45M-70.14M-43.91M-47.88M-59.27M-67.67M-62.15M-55.54M-53.89M-55.91M-63.59M-44.54M-36.95M-52.93M-39.24M-29.86M-27.32M-12.92M
Net Cash Flow (Quarter)
-13.36M-33.48M-15.86M-88.80M11.53M-21.68M-12.45M48.03M44.83M-85.51M13.91M-32.12M119.63M-119.43M23.98M-32.76M9.88M-14.52M13.87M-21.38M